Journal article

Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential

Michael Whitehead, Andrew Osborne, Peter S Widdowson, Patrick Yu-Wai-Man, Keith R Martin

JOURNAL OF DIABETES RESEARCH | HINDAWI LTD | Published : 2019

Abstract

Diabetic retinopathy (DR) is the commonest cause of blindness in the working-age population of the developed world. The molecular pathophysiology of DR is complex, and a complete spatiotemporal model of the disease is still being elucidated. Recently, a role for angiopoietin (Ang) proteins in the pathophysiology of DR has been proposed by several research groups, and several aspects of Ang signalling are being explored as novel therapeutic strategies. Here, we review the role of the Ang proteins in two important forms of DR, diabetic macular oedema and proliferative diabetic retinopathy. The function of the Ang proteins in regulating blood vessel permeability and neovascularisation is discus..

View full abstract

Grants

Awarded by Clinician Scientist Fellowship Award


Funding Acknowledgements

The authors would like to acknowledge all of the funding bodies who have contributed to the writing of this manuscript, and in particular, the core support grant from Wellcome Trust and MRC to the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. MW and PYWM are funded by the Medical Research Council (UK) grants. MW, PYWM, and AO receive support from the Novo Nordisk UK Research Foundation, the Cambridge Eye Trust, and the Jukes Glaucoma Research Fund. AO, PYWM, and KRM also hold Fight for Sight UK awards. PYWM is also supported by a Clinician Scientist Fellowship Award (G1002570), the Isaac Newton Trust, the UK National Institute for Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration, and the NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Research in the laboratory is supported by core funding from Wellcome Trust and MRC to the Wellcome Trust-MRC Cambridge Stem Cell Institute.